---
type: synthesis
title: Targeted Therapeutics and Immunotherapy Landscape in Triple-Negative Breast Cancer
tags: [synthesis, therapeutics, tnbc, akt-inhibitors, immunotherapy, oncology, precision-medicine]
created: 2026-08-17
updated: 2026-08-17
sources:
  - "[[tnbc-akt1-alphafold-docking-manuscript]]"
  - "[[tnbc-analytics-suite]]"
aliases: [TNBC Therapeutics Synthesis, Precision Oncology in TNBC]
---

# Targeted Therapeutics and Immunotherapy Landscape in Triple-Negative Breast Cancer

## Overview
Because [[triple-negative-breast-cancer]] lacks estrogen, progesterone, and HER2 receptors, modern oncology classifies TNBC into actionable molecular subtypes based on multi-omics profiling. This synthesis summarizes the computational identification and clinical deployment of targeted agents and immunotherapies.

```mermaid
graph TD
    TNBC[[triple-negative-breast-cancer]] --> A[PI3K-Akt Hyperactivation: [[pi3k-akt-mtor-signaling-pathway]]]
    TNBC --> B[Immune Infiltrate & PD-L1: [[immune-deconvolution-tme]]]
    TNBC --> C[DNA Damage Repair Deficits: BRCA1/2 Homologous Recombination]
    
    A --> D[Allosteric AKT Inhibition: [[mk-2206]]]
    A --> E[ATP-Competitive AKT Inhibition: [[ipatasertib]]]
    B --> F[Immune Checkpoint Blockade: [[pembrolizumab]]]
    C --> G[PARP Inhibitors: Olaparib, Talazoparib]
```

## Comparative Therapeutic Matrix

| Therapeutic Class | Key Agent(s) | Mechanism of Action | Biomarker / Computational Readout | Status in TNBC |
| :--- | :--- | :--- | :--- | :--- |
| **Allosteric AKT Inhibitor** | [[mk-2206]] | Binds PH-kinase interdomain cavity ($\Delta G = -9.4\text{ kcal/mol}$); locks [[akt1-kinase]] in closed state | [[wgcna-coexpression-networks]] *AKT1* hub centrality; *PIK3CA* / *PTEN* loss | Preclinical / Clinical trials |
| **ATP-Competitive AKT Inhibitor** | [[ipatasertib]] | Competes with ATP in catalytic kinase cleft ($\Delta G = -8.2\text{ kcal/mol}$) | High *AKT1* transcript expression; *PTEN* loss | Phase II/III trials (LOTUS, IPATunity130) |
| **Immune Checkpoint Blockade** | [[pembrolizumab]] | IgG4 mAb blocking PD-1 (*PDCD1*) receptor on cytotoxic T-cells | [[immune-deconvolution-tme]] high CD8+ T-cell score; $\text{CPS} \ge 10$ | FDA Approved (KEYNOTE-522, KEYNOTE-355) |
| **PARP Inhibitors** | Olaparib, Talazoparib | Traps PARP1/2 on single-strand breaks; synthetic lethality in HR-deficient cells | Germline/somatic *BRCA1*/*BRCA2* pathogenic variants in [[clinvar]] | FDA Approved (OlympiAD, EMBRACA) |

## Related Wiki Pages
- [[triple-negative-breast-cancer]]
- [[pi3k-akt-mtor-signaling-pathway]]
- [[akt1-kinase]]
- [[mk-2206]]
- [[ipatasertib]]
- [[pembrolizumab]]
- [[immune-deconvolution-tme]]
- [[transcriptome-to-structure-drug-discovery]]
